Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806807 | 0.84 | L3MBTL1 (0.53) | L3MBTL1EPHX1ACHEBRD4CREBBP | |
| SCHEMBL5840448 | 0.84 | L3MBTL1 (0.53) | L3MBTL1EPHX1ACHEBRD4CREBBP | |
| SCHEMBL5840240 | 0.81 | L3MBTL1 (0.49) | L3MBTL1EPHX1ACHEPIM1MARK3 | |
| SCHEMBL587407 | 0.74 | L3MBTL1 (0.53) | L3MBTL1EPHX1ACHEBRD4CREBBP | |
| SCHEMBL17486616 | 0.72 | MAPT (0.47) | L3MBTL1MAPTPKMMEN1KMT2A | |
| SCHEMBL17485274 | 0.72 | MAPT (0.47) | L3MBTL1MAPTPKMMEN1KMT2A | |
| SCHEMBL1196432 | 0.72 | L3MBTL1 (0.62) | L3MBTL1EPHX1ACHEBRD4CREBBP | |
| SCHEMBL8560375 | 0.72 | L3MBTL1 (0.67) | L3MBTL1MAPTEPHX1MEN1KMT2A | |
| SCHEMBL5805921 | 0.71 | L3MBTL1 (0.47) | L3MBTL1EPHX1ACHEBRD4CREBBP | |
| SCHEMBL5840385 | 0.71 | MAPT (0.44) | MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138423-B2 | Diseases mediated by tachykinins and for seritonin reuptake transporter protein as reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | BRISTOL-MEYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | TPH1, SLC6A4, HTR1D | L3MBTL1 2793/4885MAPT 2859/4885PKM 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.